Related references
Note: Only part of the references are listed.Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients
A. Romero et al.
ANNALS OF ONCOLOGY (2012)
Assessment of Topoisomerase II α Status in Breast Cancer by Quantitative PCR, Gene Expression Microarrays, Immunohistochemistry, and Fluorescence in Situ Hybridization
Atocha Romero et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients
I. Gounaris et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer
M. Martin et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features
Emilia Montagna et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Intensified neoadjuvant chemotherapy in early-responding breast cancer:: Phase III randomized GeparTrio study
Gunter von Minckwitz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Measurement of residual breast cancer burden to predict survival after Neoadjuvant chemotherapy
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: Relation to response patterns on MRI
Hyun Jung Kim et al.
ACTA ONCOLOGICA (2007)
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
HD Bear et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update
M Kaufmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors
V Guarneri et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy
AB Chagpar et al.
ANNALS OF SURGERY (2006)
Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy
BT Hennessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
American joint committee on cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome
LA Carey et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer
E Yeh et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2005)
A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival
KN Ogston et al.
BREAST (2003)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
